Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
EXMEX ,Thanks for post ,and your other good posts
sharehunter3, I'd better leave that subject for now .
exmex did not see it ,assume has been removed before seen this thread
now curious , as find your posts helpful is there any other way you could word your post
I see my post from last night on the vesting date has been removed.
https://metro.co.uk/2020/10/31/second-wave-to-peak-in-weeks-with-massive-spike-just-before-christmas-13511638/?ito=push-notification&ci=46257&si=12283585
Wonder if Father Christmas will be allowed to deliver his parcels.
Well at least we should be looking forward to an SP over 20 according to last weekends predictions.
Weirdly, a lockdown will take some pressure off the testing system and give it time to expand. I was hoping everything would have been in place by now, but if they can get it up and running in a month I'll tip my hat. I would be chuffed if the testing is in place along with a low infection base.
SO much recruitment so many jobs been advertised
The Company intends to invest both organically and through M&A in establishing a direct sales force in certain markets. Novacyt plans to establish a strong commercial infrastructure in the UK, where a significant investment in the diagnostics market is taking place. In addition, it is in the process of evaluating the best model to operate in the US, the world's largest IVD market. It is also considering certain key mainland European markets. In the rest of the world, Novacyt will continue to develop its successful distributor and partnership sales model.
strategic acquisitions.
The growth strategy aims to enable Novacyt to continue to grow the size of the core business but also to accelerate this through strategic acquisitions. The Directors believe the strong demand for COVID-19 diagnostic testing will continue through the next few months and well into next year, which will underpin the ongoing financial transformation of the Group and its trajectory towards becoming a market leader in respiratory and transplant clinical diagnostics.
With the £millions ncyt coming in weekly also find this interesting i
Respiratory and transplant are both high-margin, fast-growing IVD markets where the Company already has expertise, including COVID-19 and EBV and BKV products launched last year. Novacyt intends to leverage the new customers and brand position it has established during the COVID-19 pandemic to further penetrate these markets through 2021 and beyond. Importantly, Novacyt will use the skills, infrastructure and experience of both its business divisions (Primerdesign and Lab21) to deliver solutions that utilise the Group's protein and molecular diagnostic capabilities.
Find reading and researching this rns from 17th September ,so much information even in this of rns in my opinion
Next stage of growth
The Directors have identified specific growth opportunities in the large, fast-growing diagnostics market. Supported by its core clinical diagnostics capabilities of IVD product development, manufacturing, regulatory and commercialisation, the Company remains committed to creating shareholder value through its three-pillar strategy of organic, R&D and acquisitive growth, which will be focused within the respiratory and transplant bacterial and viral diagnostic markets.
Respiratory and transplant are both high-margin, fast-growing IVD markets where the Company already has expertise, including COVID-19 and EBV and BKV products launched last year. Novacyt intends to leverage the new customers and brand position it has established during the COVID-19 pandemic to further penetrate these markets through 2021 and beyond. Importantly, Novacyt will use the skills, infrastructure and experience of both its business divisions (Primerdesign and Lab21) to deliver solutions that utilise the Group's protein and molecular diagnostic capabilities.
The growth strategy aims to enable Novacyt to continue to grow the size of the core business but also to accelerate this through strategic acquisitions. The Directors believe the strong demand for COVID-19 diagnostic testing will continue through the next few months and well into next year, which will underpin the ongoing financial transformation of the Group and its trajectory towards becoming a market leader in respiratory and transplant clinical diagnostics.
The Company intends to invest both organically and through M&A in establishing a direct sales force in certain markets. Novacyt plans to establish a strong commercial infrastructure in the UK, where a significant investment in the diagnostics market is taking place. In addition, it is in the process of evaluating the best model to operate in the US, the world's largest IVD market. It is also considering certain key mainland European markets. In the rest of the world, Novacyt will continue to develop its successful distributor and partnership sales model.
Novacyt has demonstrated during the last six months the financial value and profitability it can generate in the right clinical IVD markets with a low-cost base. To achieve additional revenue, the Company will continue to invest in R&D to drive new product development. Novacyt also plans to accelerate revenues and additional profitability through selective and accretive acquisitions. These actions are expected to replace any potential lost revenues from a future decline in COVID-19 testing.
Market dynamics to support strategy
The focus on the importance of diagnostics, as a result of the COVID-19 pandemic, is leading to increased opportunities and anticipated significant new investment in the sector.
IVD market
Astra Zeneca don't actually have a diagnostics arm. My contact there in the past has said they would not be interested acquiring diagnostics as not their field.
Seeing how lucrative NCYT have been within the partnership must give AZN food for thought to become involved within the field in the future.. I've not had any further confirmation that AZN attitude towards this has changed from my discussion a while ago but watch this space..
if a national lockdown , for a number of weeks ,if the Government ,relax the rules over Christmas even for 1 or 2 days and let larger numbers meet indoors ,would people view that as to much of a risk of virus spreading again ,
Will ncyt Antigen test be the one to help out if even more testing is needed .
IF another national lockdown . would likely do so much damage to business ,and Jobs ,
Boris Johnson set to announceBoris Johnson set to announce national lockdownheadlines 11hrs past The Telegraph
really hoping ,it does not happen
if enough proper testing would like to think might not need a national lockdown .
Morning I trying to work out your point
With Astra and nyct
Zeeco
Astrazeneca..
Shares in issue 1.312 billion
Market cap 103 billion
P/E 76.47
Novacyt
Shares in issue 71 million
Market cap circa 710 million
P/E 1 or 2?
50% of AZ market cap is 51.5 billion
NCYT market cap at £40 = £2.84 billion
Zeccoshares this is highly possible now, do remember AstraZeneca have approx 20 shares for everyone of ours so it's not as daft as you think. If we bring an appropriate additional product to market the sp movement will be insane. With the frightening new developments and if it's for the greater good I could see us having a friendly takeover very soon but GM running the "division" All imho stay safe.
Almost half the price of AstraZeneca??
wow covid more lockdowns coming . Novacyt going to make huge amounts of money in now thinking £30-40 sp here